{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:26:51Z","timestamp":1757611611081,"version":"3.44.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>\n                                 <jats:sup>177<\/jats:sup>Lu-DOTATATE\/DOTATOC peptide receptor radionuclide therapy (PRRT) has demonstrated potential for treating pediatric neuroblastoma (NB), and in clinical practice can be measured dosimetry by multi\u2013time point (MTP) dosimetry. However, the high workload and limited patient compliance associated with MTP restrict its application. Consequently, single time point (STP) dosimetry approaches have emerged as a promising alternative, though their effectiveness in pediatric populations has not been thoroughly investigated. This study aimed to assess the dosimetric determination of <jats:sup>177<\/jats:sup>Lu-DOTATATE\/DOTATOC in pediatric neuroblastoma patients to determine whether STP could serve as a viable replacement for MTP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>A total of 24 pediatric NB patients who received 1 to 2 cycles of <jats:sup>177<\/jats:sup>Lu-DOTATATE or <jats:sup>177<\/jats:sup>Lu-DOTATOC underwent dosimetric measurement of lesions and critical organs using the 96 hours single time point (STP<jats:sub>H<\/jats:sub>) dosimetry method proposed by H\u00e4nscheid and colleagues. The results were compared with those obtained from standard MTP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In patients treated with <jats:sup>177<\/jats:sup>Lu-DOTATATE, the mean relative deviation absolute values of the STP<jats:sub>H<\/jats:sub>-calculated absorbed dose from MTP were &lt;10% for lesions, kidneys, bone marrow, liver, and spleen, with Pearson correlation coefficients of 0.99, 0.93, 0.97, 0.84, and 0.84, respectively. In patients treated with <jats:sup>177<\/jats:sup>Lu-DOTATOC, the mean relative deviation absolute values for kidneys, spleen, and bone marrow were &lt;10%, with Pearson correlation coefficients of 0.97, 0.77, 0.35, 0.48, and 0.93 for lesions, kidneys, bone marrow, liver, and spleen, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The findings confirm that the 96 hours STP<jats:sub>H<\/jats:sub> method can reliably replace MTP for dosimetric assessment in pediatric NB patients treated with <jats:sup>177<\/jats:sup>Lu-DOTATATE and performed well in renal dosimetry for <jats:sup>177<\/jats:sup>Lu-DOTATOC therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006029","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T01:00:10Z","timestamp":1750122010000},"page":"921-926","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of Single Time Point Dosimetry Application in 177Lu-DOTATATE\/DOTATOC-treated Pediatric Neuroblastoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Xingyao","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Graduate, Shandong First Medical University and Shandong Academy of Medical Sciences"},{"name":"Department of Nuclear Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Jinan City People\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-8180","authenticated-orcid":false,"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"R1-20250903","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-017-0686-8","article-title":"11q deletion in neuroblastoma: a review of biological and clinical implications","volume":"16","author":"Mlakar","year":"2017","journal-title":"Mol Cancer"},{"key":"R2-20250903","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.soc.2020.11.010","article-title":"Management of neuroblastoma in pediatric patients","volume":"30","author":"Croteau","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"key":"R3-20250903","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/RLU.0000000000003577","article-title":"Feasibility and therapeutic potential of combined peptide receptor radionuclide therapy with intensive chemotherapy for pediatric patients with relapsed or refractory metastatic neuroblastoma","volume":"46","author":"Fathpour","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R4-20250903","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI procedure standard\/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"R5-20250903","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-018-0232-9","article-title":"Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (\u2018lutate\u2019) therapy","volume":"5","author":"Willowson","year":"2018","journal-title":"EJNMMI Phys"},{"key":"R6-20250903","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"key":"R7-20250903","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.6061\/clinics\/2019\/e835","article-title":"Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning","volume":"74","author":"Sapienza","year":"2019","journal-title":"Clinics (Sao Paulo)"},{"key":"R8-20250903","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2967\/jnumed.115.159012","article-title":"MIRD pamphlet no. 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy","volume":"57","author":"Ljungberg","year":"2016","journal-title":"J Nucl Med"},{"key":"R9-20250903","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","author":"H\u00e4nscheid","year":"2018","journal-title":"J Nucl Med"},{"key":"R10-20250903","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/mp.12886","article-title":"Technical note: single time point dose estimate for exponential clearance","volume":"45","author":"Madsen","year":"2018","journal-title":"Med Phys"},{"key":"R11-20250903","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40658-021-00409-z","article-title":"Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT\/CT study","volume":"8","author":"Chicheportiche","year":"2021","journal-title":"EJNMMI Phys"},{"key":"R12-20250903","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2967\/jnumed.120.256255","article-title":"A novel time-activity information-sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT\/CT after 177Lu-DOTATATE","volume":"62","author":"Devasia","year":"2021","journal-title":"J Nucl Med"},{"key":"R13-20250903","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2967\/jnumed.122.265338","article-title":"Single-time-point imaging for dosimetry after [177Lu]lu-DOTATATE: accuracy of existing methods and novel data-driven models for reducing sensitivity to time-point selection","volume":"64","author":"Wang","year":"2023","journal-title":"J Nucl Med"},{"key":"R14-20250903","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.120.254656","article-title":"Feasibility of single-time-point dosimetry for radiopharmaceutical therapies","volume":"62","author":"Hou","year":"2021","journal-title":"J Nucl Med"},{"key":"R15-20250903","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med Res Rev"},{"key":"R16-20250903","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40262-014-0134-5","article-title":"Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings","volume":"53","author":"Mahmood","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R17-20250903","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","article-title":"MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy","volume":"53","author":"Dewaraja","year":"2012","journal-title":"J Nucl Med"},{"key":"R18-20250903","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry\u2014standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"key":"R19-20250903","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment","volume":"54","author":"Sandstr\u00f6m","year":"2013","journal-title":"J Nucl Med"},{"key":"R20-20250903","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7150\/thno.92487","article-title":"Long-term nephrotoxicity after PRRT: myth or reality","volume":"14","author":"Baum","year":"2024","journal-title":"Theranostics"},{"key":"R21-20250903","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2967\/jnumed.122.264594","article-title":"Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy","volume":"64","author":"Brosch-Lenz","year":"2023","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:00:29Z","timestamp":1756933229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006029","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"2025-03-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}